<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001635'>Heart failure</z:hpo> is a clinical syndrome that results when the heart is unable to provide sufficient blood flow to meet metabolic requirements or accommodate systemic venous return </plain></SENT>
<SENT sid="1" pm="."><plain>This common condition affects over 5 million people in the United States at a cost of $10-38 billion per year </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001635'>Heart failure</z:hpo> results from injury to the myocardium from a variety of causes including <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Less common etiologies include <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo>, valvular disease, <z:mp ids='MP_0001856'>myocarditis</z:mp>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, systemic toxins, and cardiotoxic drugs </plain></SENT>
<SENT sid="4" pm="."><plain>As the heart fails, patients develop symptoms which include <z:hpo ids='HP_0002094'>dyspnea</z:hpo> from <z:mp ids='MP_0010018'>pulmonary congestion</z:mp>, and peripheral <z:hpo ids='HP_0000969'>edema</z:hpo> and <z:hpo ids='HP_0001541'>ascites</z:hpo> from impaired venous return </plain></SENT>
<SENT sid="5" pm="."><plain>Constitutional symptoms such as <z:hpo ids='HP_0002018'>nausea</z:hpo>, lack of appetite, and <z:mp ids='MP_0002899'>fatigue</z:mp> are also common </plain></SENT>
<SENT sid="6" pm="."><plain>There are several compensatory mechanisms that occur as the failing heart attempts to maintain adequate function </plain></SENT>
<SENT sid="7" pm="."><plain>These include increasing cardiac output via the Frank-Starling mechanism, increasing ventricular volume and wall thickness through ventricular remodeling, and maintaining tissue perfusion with augmented mean arterial pressure through activation of neurohormonal systems </plain></SENT>
<SENT sid="8" pm="."><plain>Although initially beneficial in the early stages of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> of these compensatory mechanisms eventually lead to a vicious cycle of worsening <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment strategies have been developed based upon the understanding of these compensatory mechanisms </plain></SENT>
<SENT sid="10" pm="."><plain>Medical therapy includes <z:mp ids='MP_0001762'>diuresis</z:mp>, suppression of the overactive neurohormonal systems, and augmentation of contractility </plain></SENT>
<SENT sid="11" pm="."><plain>Surgical options include ventricular resynchronization therapy, surgical ventricular remodeling, ventricular assist device implantation, and heart transplantation </plain></SENT>
<SENT sid="12" pm="."><plain>Despite significant understanding of the underlying pathophysiological mechanisms in <z:hpo ids='HP_0001635'>heart failure</z:hpo>, this disease causes significant morbidity and carries a 50% 5-year mortality </plain></SENT>
</text></document>